Inozyme Pharma, Inc. (INZY)

4.5400 -0.1100 (-2.37%) At close: 04:00PM EDT

Inozyme Pharma, Inc.

321 Summer Street
Suite 400
Boston, MA 02210
United States
(857) 330-4340
https://www.inozyme.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 59

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Douglas A. Treco Ph.D.	CEO & Chairman	591.88k	N/A	1958
Mr. Axel Bolte M.B.A., M.Sc.	Co-Founder, Senior Advisor & Director	1.16M	N/A	1972
Mr. Sanjay S. Subramanian M.B.A., M.S.	Senior VP, CFO, Principal Accounting Officer & Corporate Secretary	626.23k	N/A	1977
Dr. Matthew Winton Ph.D.	Senior VP & COO	526.43k	N/A	1978
Dr. Demetrios Braddock M.D., Ph.D.	Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer	N/A	N/A	N/A
Dr. Soojin Kim Ph.D.	Senior VP & Chief Technical Operations Officer	N/A	N/A	N/A
Dr. David Thompson M.A., M.S., Ph.D.	Senior VP, Chief Scientific Officer & Chief Development Officer	N/A	N/A	N/A
Mr. Stefan Riley	Director of Investor Relations	N/A	N/A	N/A
Ms. Gayle Gironda	Senior VP & Chief People Officer	N/A	N/A	N/A
Dr. Yves Sabbagh Ph.D.	Chairman of Scientific Advisory Board & Senior VP	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate governance

Inozyme Pharma, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.